Maestas Nicholas 4

What Happened Nicholas Maestas, Chief Financial Officer of Tempest Therapeutics (TPST), received a derivative award on March 31, 2026 covering 140,000 shares. The Form 4 reports the acquisition as an award/ grant (transaction code A) with a reported price of $0.00 — meaning no cash was paid at grant. This is a compensation grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-03-31; Form 4 filed 2026-04-02. No late-filing indicator is shown in the provided data.
• Security: derivative award (option) covering 140,000 shares; reported price $0.00.
• Vesting (footnote): 25% of the option vests on March 31, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service.
• Transaction code: A (award/grant).
• Shares owned after transaction: not specified in the provided filing.

Context This was a standard equity-compensation grant to an executive (option-style award with a multi-year vesting schedule). Such grants are routine for aligning management with shareholder interests; they are different from open-market purchases (which can signal personal bullishness) or immediate exercises/sales.